anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Malignant Triton Tumors (MTTs) are a rare and aggressive subtype of malignant peripheral nerve sheath tumors (MPNSTs), often associated with neurofibromatosis type 1. This case report describes a unique instance of recurrent sporadic MTT within the carotid sheath in a 33-year-old male without any personal or familial history of neurofibromatosis. The patient initially presented with a biopsy-confirmed MTT in the right neck, involving the carotid body and brachial plexus, and underwent partial resection, radiation therapy, and chemotherapy. Six months later, the patient presented with recurrent MTT, and subsequently underwent radical tumor resection, segmental right carotid artery resection, and deep femoral vein interposition. Recovery was complicated by hematoma formation, and the patient developed vocal fold paralysis and a left vocal fold cyst, necessitating further surgeries. Yearly follow-ups for 8 years revealed no recurrence. This case emphasizes the importance of comprehensive patient evaluation, including clinical history, imaging, and biopsy findings, for accurate diagnosis and prompt surgical intervention in managing such rare and aggressive tumors. Further research is needed to identify novel therapies and improve survival rates for patients with MTTs.
A mechanism is provided in a data processing system comprising at least one processor and at least one memory, the at least one memory comprising instructions executed by the at least one processor to cause the at least one processor to implement a healthcare analytics management system. A healthcare analytics development sub-system of the healthcare analytics management system develops an analytics pipeline of a set of analytics assets for a selected healthcare based on a set of business needs for a healthcare analytics client and a healthcare analytics model based on the set of analytics assets and the set of business needs. The healthcare analytics model links to the analytics pipeline. A model deployment module of a healthcare analytics operation sub-system of the healthcare analytics management system deploys the healthcare analytics model on a set of computing devices of the selected healthcare consumer. Responsive to a model monitoring module of the healthcare analytics operation sub-system detecting a performance deviation of the deployed healthcare analytics model for performance deviation from the set of business needs for the healthcare analytics client, a model feedback module of the healthcare analytics operation sub-system determines improvement needs for the healthcare analytics model. The model feedback module feeds the improvement needs back to the healthcare analytics development sub-system. The healthcare analytics development sub-system customizes the healthcare analytics model based on the improvement needs
The invention relates to an intra-intestinal nutrient emulsion for tumor patients and a preparation method thereof, belonging to the technical field of nutrient medicament preparation. The intra-intestinal nutrient emulsion is prepared by preparation of primary emulsion, dilution, storage, packaging, and sterilization. The intra-intestinal nutrient emulsion contains protein, fat, carbohydrates, vitamins, minerals, microelements, dietary fibers and other nutrients. The energy distribution of the intra-intestinal nutrient emulsion is as follows: 18% of protein, 50% of fat and 32% of carbohydrates, thereby increasing the energy supply ratio of fat and reducing the energy supply ratio of carbohydrates. The intra-intestinal nutrient emulsion is designed according to the tumor patients and meets the metabolism need of the tumor patients. The whole production process of the emulsion is carried out under nitrogen protection, and through sterilization of a rotary sterilization kettle, the effective ingredients of the product can be better retained.
Participant will receive Voluntary Rate Exercise (stationary cycling) and psychotherapy for pain (I-STOP). Exercise (supervised) will be offered 3 days/week. I-STOP will be offered 1 day/week.
Approximately 1 in 1,000 children born in the US have hip dislocation and 10 in 1,000 have hip subluxation requiring surgical intervention. Pain after major hip surgery in children is severe, yet there is no agreement on the most effective method for pain control. Post-operative pain modalities including lumbar epidural catheters (LEC), lumbar plexus catheters (LPC) and intravenous patient controlled analgesia (IV-PCA) have been described. IV-PCA has historically been the standard of care in spite of its numerous associated side effects. Regional anesthesia modalities have gained popularity because of superior pain control with lower opioid requirements.

In this study, the investigators describe the first prospective randomized controlled trial comparing lumbar plexus catheter to alternatives for post-operative pain management in children after major hip surgery. The investigators hypothesized that LPC would be as safe and efficacious as LEC and IV-PCA with the added advantage of a decreased length of stay. The investigators primary aim was to compare hospital length of stay. Secondary aim was to compare pain scores, opioid consumption and opioid-related side effects.
For Project 3, only individuals who have previously been implanted with an epidural stimulator will be invited to participate. They will have only one stimulation session. We will not offer participants to undergo implantation surgery.
The invented medicine is a rare specimen of good drug nowadays for treating rheumatic cadiopathy, and coronary heart disease (palpitation, syncope, oppressed feeling in chest, dyspnea, asthma, cough, cyanosis and arrhythmia). The recipe consists of old tea tree root, clerodendron bungei, cardamine hirsuta, fetid cassia seed, and trichosanthes fruit five traditional Chinese medicinal herbs and is prepared up through strict scientific preparation process. The above medicines are air dried, ground into fine powder, sieved and bagged (5g per bag). Taking after mixed with white sugar or crystal sugar and boiling water, and taking one bag for each pm and each am, it will become effective within five days for the above mentioned disease, and the result is obvious after 10 days. The patient of rheumatic cadiopathy or coronary arteriosclerotic heart disease will be fully recovered after half year and there is no relapse. Said product can be made into tablets, capsules, honey mixed bolus or.....
BACKGROUND AND AIMS: Image-enhanced endoscopy has attracted attention as a method for detecting inflammation and predicting outcomes in patients with ulcerative colitis (UC); however, the procedure requires specialist endoscopists. Artificial intelligence (AI)-assisted image-enhanced endoscopy may help nonexperts provide objective accurate predictions with the use of optical imaging. We aimed to develop a novel AI-based system using 8853 images from 167 patients with UC to diagnose "vascular-healing" and establish the role of AI-based vascular-healing for predicting the outcomes of patients with UC.
METHODS: This open-label prospective cohort study analyzed data for 104 patients with UC in clinical remission. Endoscopists performed colonoscopy using the AI system, which identified the target mucosa as AI-based vascular-active or vascular-healing. Mayo endoscopic subscore (MES), AI outputs, and histologic assessment were recorded for 6 colorectal segments from each patient. Patients were followed up for 12 months. Clinical relapse was defined as a partial Mayo score >2 RESULTS: The clinical relapse rate was significantly higher in the AI-based vascular-active group (23.9% [16/67]) compared with the AI-based vascular-healing group (3.0% [1/33)]; P = .01). In a subanalysis predicting clinical relapse in patients with MES ≤1, the area under the receiver operating characteristic curve for the combination of complete endoscopic remission and vascular healing (0.70) was increased compared with that for complete endoscopic remission alone (0.65).
CONCLUSIONS: AI-based vascular-healing diagnosis system may potentially be used to provide more confidence to physicians to accurately identify patients in remission of UC who would likely relapse rather than remain stable.
Subjects are given 300 mg / 7 days of rifampicin to induce CYP3A4. Midazolam clearance is measured on the 8th day.
Participants ages 1 to 6 years old were administered daptomycin 12 mg/kg, infused once daily, IV over 60 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
Patients receive cemiplimab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may transition to SOC HHI therapy. Patients undergo CT or MRI scans and collection of blood samples throughout the trial. Patients also undergo biopsies during screening and on study.
PURPOSE: Stereotactic body radiation therapy (SBRT) is increasingly being used to treat spine metastases. Current post-SBRT imaging surveillance strategies in this patient population may benefit from a more data-driven and personalized approach. The objective of this study was to develop risk-stratified post-SBRT magnetic resonance imaging (MRI) surveillance strategies using quantitative methods.
METHODS AND MATERIALS: Adult patients with bony spine metastases treated with SBRT between 2008 and 2021 and who had at least 2 follow-up spine MRIs were reviewed retrospectively. A recursive partitioning analysis model was developed to separate patients into different risk categories for post-SBRT progression anywhere within the spine. Imaging intervals were derived for each risk category using parametric survival regression based on multiple expected spine progression rates per scan.
RESULTS: A total of 446 patients and 1039 vertebral segments were included. Cumulative incidence of spine progression was 19.2% at 1 year, 26.7% at 2 years, and 35.3% at 4 years. The internally validated risk stratification model was able to divide patients into 3 risk categories based on epidural disease, paraspinal disease, and Spinal Instability Neoplastic Score category. The 4-year risk of spine progression was 23.4%, 39.0%, and 51.8%, respectively, for the low-, intermediate-, and high-risk groups. Using an expected per-scan spine progression rate of 3.75%, the low-risk group would require follow-up scans every 6.0 months (95% CI, 4.9-7.6) and the intermediate-risk group would require surveillance every 3.1 months (95% CI, 2.6-3.7). At an expected spine progression rate of 5%, the high-risk group would require surveillance every 1.3 months (95% CI, 1.1-1.6) during the first 13.2 months after SBRT and every 5.9 months thereafter (95% CI, 2.8-12.3).
CONCLUSIONS: Data-driven follow-up MRI surveillance intervals at a range of expected spine progression rates have been determined for patients at different risks of spine progression based on an internally validated, single-institution risk stratification model.
The invention relates to medicine and concerns the preparation of a cellular graft from fetal tissues. The inventive method consists in isolating cells of various organs of an abortive fetus of 17-21 weeks of an intrauterine growth and with the weight of 150-450 g, suspending said cells, selecting suspensions with a high content of regional stem cells, regional blast cells provided with high migration properties, specialized cells (like pancreas β-cells) and biologically active substances taken from fetal cells. The number of cells in the graft ranges from 25x104 to 10x107, the viability of all cells of the graft must be not less than 80-90 %, the expression of histocompatibility antigens of class II does not exceed 8-15 %; a spontaneous activity Ca2+/M2+ of a depended endonuclease is not less than 0.1 conventional units; an induced activity Ca2+/M2+ of a dependent endonuclease ranges from 0.3 to 9 conventional units (c.u.), a representation of a marker CD 95 is less than or equal to 5 %. The inventive graft also comprises growth indexes, and/or migration indexes, and/or a specific protein, and/or antioxidants, and/or a carrier of oxygen active modifications, and/or adaptogenes, and also other substances possessing anti-inflammatory and bacteriostatic action. The cellular grafts produced from fetal tissues using the inventive method are efficient and safe for curing large number of diseases.
UNLABELLED: Neonates and infants surviving critical illness show impaired growth during critical illness and are at risk for later neuropsychological impairments. Early identification of individuals most at risk is needed to provide tailored long-term follow-up and care. The research question is whether early growth during hospitalization is associated with growth and neuropsychological outcomes in neonates and infants after pediatric intensive care unit admission (PICU). This is a secondary analysis of the PEPaNIC trial. Weight measurements upon PICU admission, at PICU discharge, at hospital discharge, at 2- and 4-year follow-up, and of different subgroups were compared using (paired) t-tests. Multiple linear regression analyses were performed to investigate the association between early growth in weight measures and neuropsychological outcomes at 4-year follow-up. One hundred twenty-one infants were included, and median age upon admission was 21 days. Growth in weight per week was less than the age-appropriate norm, resulting in a decrease in weight-for-age Z-score during hospitalization. Weight is normalized at 2- and 4-year follow-up. Weight gain in kilograms per week and change in weight Z-score were not associated with neurodevelopmental outcome measures at 4-year follow-up. Lower weight-for-age Z-score at PICU admission and at hospital discharge was associated only with lower weight and height Z-scores at 4-year follow-up.
CONCLUSION: Growth in weight during hospital stay of young survivors of critical illness is impaired. Worse early growth in weight is associated with lower weight and height but not with neuropsychological outcomes at 4-year follow-up.
WHAT IS KNOWN: • Critically ill neonates and infants show impaired early growth during admission and are at risk for later neuropsychological impairments. • Unraveling the association between early growth and later neuropsychological impairments is crucial since the first year of life is critical for brain development.
WHAT IS NEW: • Critically ill neonates and infants had age appropriate weight measures at 4-year follow-up. • Poor growth in weight during hospital stay was not associated with poorer cognitive, emotional, or behavioral functioning four years after critical illness.
The invention discloses an application of a DCLK1 inhibitor and a TKI in preparation of lung adenocarcinoma medicaments. The invention provides an application of a DCLK1 inhibitor and a TKI in preparation of lung adenocarcinoma medicaments. The invention also provides a lung adenocarcinoma drug, which comprises the active ingredients of a DCLK1 inhibitor and a TKI. The invention also provides application of the DCLK1 inhibitor in preparing medicines; the function of the medicine is to reverse TKI drug resistance. The invention also provides a medicine for reversing TKI drug resistance, and the active ingredient of the medicine is a DCLK1 inhibitor. The invention discovers that the application of the DCLK1 specific small molecule inhibitor is hopeful to reverse EGFR-TKI drug resistance and breaks through the bottleneck of clinical lung adenocarcinoma postline treatment. The invention has clinical conversion value and great significance for treating lung adenocarcinoma.
Investigator aimed to assess blood level of sevoflurane and desflurane during two lung ventilation and one lung ventilation. The investigators will use Gas Chromatography for define drugs levels. 16 patients with ASA I-III patients who undergo thoracotomy and abdominal surgery will be recruited to this study. Patients will divided in to the 2 groups. %1.5 Sevoflurane will apply in Group S and %6 Desflurane will apply in Group D during anesthesia maintenance. Each groups will divide 2 subgroups which are one lung ventilation groups and two lung ventilation groups. Two lung ventilation will be performed to Group Sa and Group Da, one lung ventilation will be performed to Group Sb and Group Db. Sequential blood samples will be taken from both arterial and central venous canula at the same time point. First blood samples will be taken at 40. minutes of anesthesia. Sequential samples will be taken at interval of 10 minutes during two lung ventilation. In one lung ventilation second blood samples will be taken at the 10. minutes of one lung ventilation. After than at the interval of 10 minutes, collection of blood samples both arterial and central venous will be continue.

All collection will assess with gas chromatography.
Method of route planning for physical training purposes, wherein during movement along the planned route the heart rate of the person performing the training should be kept within a given range; prior to the training the load profile of the person performing the training is recorded and the map data of the area relevant to the training is stored electronically; then, based on the recorded data pursuant to the calculation of costs it is determined whether the load is expected to fall within the permitted range. When determining the load profile of the person performing the training, the time elapsed since the beginning of the training and the amount of total load during the given elapsed time are taken into consideration, as well as whether there was a previous section moving along which the body had a chance to get partially regenerated. In the course of the route wherein the course of moving along such section the level of effort has decreased compared to previous loads and the body of the person performing the training could then have a chance to at least get partially regenerated. The maximum threshold of load related to the person performing the training is also taken into consideration when determining the load profile of such person. For the calculation of the estimate there are two costs applied to each section, from which the first cost is the quantity typical of the effort made in the course of the given section, and the second cost is the cost weighted with the prior load and the regeneration, if applicable, arising in the course of a given section. In the course of the calculation step the first costs are totalized for the entire route and the route is regarded acceptable, if the totalized cost is smaller than the cost associated with the measured threshold load. In addition, with respect to each section the second costs are compared to the appropriate section of the load profile, and if the amount of the second costs exceeds the amount permitted for the given section, the route in question is not accepted and re-planning of the route is commenced.
Investigating the role of podocytes in proteinuric disease is imperative to address the increasing global burden of chronic kidney disease (CKD). Studies strongly implicate increased levels of monocyte chemoattractant protein-1 (MCP-1/CCL2) in proteinuric CKD. Since podocytes express the receptor for MCP-1 (i.e., CCR2), we hypothesized that podocyte-specific MCP-1 production in response to stimuli could activate its receptor in an autocrine manner, leading to further podocyte injury. To test this hypothesis, we generated podocyte-specific MCP-1 knockout mice (Podo-Mcp-1fl/fl) and exposed them to proteinuric injury induced by either angiotensin II (Ang II; 1.5 mg/kg/d, osmotic minipump) or Adriamycin (Adr; 18 mg/kg, intravenous bolus). At baseline, there were no between-group differences in body weight, histology, albuminuria, and podocyte markers. After 28 days, there were no between-group differences in survival, change in body weight, albuminuria, kidney function, glomerular injury, and tubulointerstitial fibrosis. The lack of protection in the knockout mice suggests that podocyte-specific MCP-1 production is not a major contributor to either Ang II- or Adr-induced glomerular disease, implicating that another cell type is the source of pathogenic MCP-1 production in CKD.
Patients who are not fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours) are randomized into the intervention or control group. In the intervention group, when the respective questionnaire thresholds are exceeded in the ePROM survey, an alarm is triggered at the treating prostate cancer center and contact is made by the center, as well as subsequent actions, if necessary.
The present invention relates to produce a composite particle (sphere particle) with organic solid component (A), in which that the particle shape dispersion phase is made of the organic solid component (A) containing plural organic solid material (resin etc.) and the assistant component (B) is eluted from the dispersion which is made by dispersing the matrix containing water-soluble assistant component (B) with at least oligosaccharide (B1). The said plural organic solid material could have different affinities to the assistant component (B). The particle could have a core-shell structure which is made of a core part containing the first organic solid material (hydrophobic resin etc.) and a shell containing the non-soluble second organic solid material (hydrophilic resin etc.) in the said organic solid material. The ratio (weight ratio) of the organic solid component (A) and assistant component (B) could be (A) / (B)=55/45~1/99. According to the above method, the composite particle (core-shell type particle etc.) corresponding to the dispersion phase could be easily produced regardless of the affinity between the dispersion phase and the matrix or the polymerization method for producing resin.
Patients receive erlotinib hydrochloride PO QD. Starting on day 15, patients also receive dovitinib lactate PO QD on days 1-5 of each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
PURPOSE:To obtain a biologically active substance effective for medical treatment from a culture efficiently and advantageously, by cultivating a microorganism belonging to the genus Bordetella in a medium containing cassamino acid, ascorbic acid, and glutathione. CONSTITUTION:A microorganism such as Bordetella pertussis, Bordella bronchiseptica, etc., belonging to the genus Bordella is cultivated in a medium containing 0.1-20g/l casamino acid, 0.01-1g/l ascorbic acid, and 0.1-5g/l glutathine. Consequently, a microorganism such as Bordetella, etc. is cultivated efficiently, pathogenic bacteria such as Bordetella pertussis, etc. are detected quickly and securely to give data useful for clinical diagnosis. A physiologically active substances such as vaccine of whooping cough, active substance or enriching insulin secretion, etc. accumulated in the culture are separaed and purified from the culture, to give a vaccine for preventing whooping cough, a physiologically active substance useful for remedying diabetes, etc. efficiently.
Hyponatremia may occur as a result of treatment with serotonergic antidepressants, including REMERON/REMERONSolTab. Cases with serum sodium lower than 110 mmol/L have been reported.

Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to falls. Signs and symptoms associated with more severe or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH).

In patients with symptomatic hyponatremia, discontinue REMERON/REMERONSolTab and institute appropriate medical intervention. Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia [see Use in Specific Populations (8.5)] .